SPYRE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $5.2M | $4.6M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $22.8M | $18.1M |
| SG&A Expense | $10.1M | $8.4M |
| Operating Income | $-27.7M | $-21.9M |
| Operating Margin | -531.7% | -473.3% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | $0 | $0 |
| Net Income | $-27.2M | $-21.7M |
| Net Margin | -523.3% | -468.8% |
| EPS (Basic) | $-0.90 | $-1.11 |
| EPS (Diluted) | $-0.90 | $-1.11 |
| Shares Outstanding (Basic) | 33.3M | 26.9M |
| Shares Outstanding (Diluted) | 33.3M | 26.9M |
| Dividends Per Share | — | — |